Poging GOUD - Vrij
Slimmer Side Effects
Newsweek US
|February 28 - March 03, 2025 (Double Issue)
Weight-loss drugs have become hugely popular but can cause gastrointestinal issues. A breakthrough could be about to change that and also make treatment more affordable
RESEARCHERS FROM ACROSS the United States believe they have developed a breakthrough weight-loss drug treatment: two new peptide compounds that could rival popular drugs like Ozempic and Wegovy, but without some of the debilitating side effects.
Dr. Robert Doyle, a medicinal chemist and professor at Syracuse University in New York, has been working on the compounds-GEP44 and KCEM1-for several years along with his collabora tors, Dr. Matthew Hayes, vice chair for basic and translational neuroscience research at the University of Pennsylvania's Perelman School of Medicine, and Dr. Christian Roth, an endocrinologist at Seattle Children's Research Institute.
Recently, they've introduced the compounds at conferences for the American Chemical Society and The Obesity Society. These compounds take a different approach to weight loss than existing medications, which can cause nausea, vomiting and gastric malaise. GLP-1 receptor targeting has been successful for weight loss but can trigger an "unwell" feeling that leads many patients to abandon treatment, Doyle told Newsweek.
"Our approach has been to partner with PYY receptors," he said, "and we're finding that we can trigger significant weight loss with essentially no nausea or vomiting."
Dit verhaal komt uit de February 28 - March 03, 2025 (Double Issue)-editie van Newsweek US.
Abonneer u op Magzter GOLD voor toegang tot duizenden zorgvuldig samengestelde premiumverhalen en meer dan 9000 tijdschriften en kranten.
Bent u al abonnee? Aanmelden
MEER VERHALEN VAN Newsweek US
Newsweek US
THE GREAT RESET
The global auto industry is at a turning point—new tech, new rules and buyers who want something different
4 mins
May 29, 2026
Newsweek US
Executive DISRUPTOR OF THE YEAR
He is changing the way Stellantis designs, builds and sells cars, righting the wrongs of the past
4 mins
May 29, 2026
Newsweek US
VISIONARY DISRUPTOR OF THE YEAR
Because of Barman's leadership, Slate will offer new-age engineering at a budget-friendly price point
2 mins
May 29, 2026
Newsweek US
Changing the Count
MLB viewership has surged in 2026, with national broadcasts drawing 44 percent more viewers than last year-the league's strongest showing in nearly a decade. The increase has been widely framed as a comeback. The drivers suggest something more structural.
1 min
May 29, 2026
Newsweek US
WHO IS THE REAL GRAHAM PLATNER?
An oyster farmer turned Maine Senate candidate's organizing-first strategy survives scandal and party resistance
15 mins
May 29, 2026
Newsweek US
The Empty Pulpit Problem
The U.S. isn't just running out of pastors, it is losing one of its most local forms of leadership.
1 mins
May 29, 2026
Newsweek US
Status Update: Taking a Digital Detox
It's a question Silicon Valley might prefer we didn't ask-but it appears Gen Z is already wondering: Is social media past its peak?
1 min
May 29, 2026
Newsweek US
Revolt of the Urban Taxpayer
WE'RE OFFICIALLY IN PRIMARY SEASON, WITH THE MID- terms in less than six months-sooner than you think. Will the Democrats take back the House? Pretty likely. The Senate? The longer the war in Iran drags on, the likelier that once-unthinkable outcome gets. But the race I can't look away from has nothing to do with the balance of power in Congress. It's the race for who will be the next mayor of Los Angeles.
2 mins
May 29, 2026
Newsweek US
SUSTAINABILITY DISRUPTOR OF THE YEAR
The electric GLC SUV maintains its eco focus—without compromise
2 mins
May 29, 2026
Newsweek US
POWERTRAIN DISRUPTOR OF THE YEAR
Unyielding commitment to full-throttle fun defines BMW's Neue Klasse
2 mins
May 29, 2026
Listen
Translate
Change font size

